Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after reporting Tuesday that the drug led ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results